Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

Also called NCT05185804

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 399 participants (enrolled count) (from the registry)
Sponsor
PharmaDiall Ltd. (from the registry)
Registry
  • NCT NCT05185804
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05185804. Randomized; no masking; primary purpose treatment. Start 2021-02-08 (actual); primary completion 2021-08-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
Condition
COVID-19
Condition
Venous Thromboembolism
Intervention (Drug)
Dimolegin
Intervention (Drug)
Clexane
Lead sponsor
PharmaDiall Ltd. (class: other)

Record details

Record id
cardio:ct-nct05185804
Content hash
0c2d259502a8c8661e3a404555482874f1923f447b657600da31a003f3ef35a3